« What To Do With The Not-Quite-Worthless |
| Maitotoxin: It's On, All Right »
June 28, 2010
That Schering-Plough Lawsuit Isn't Going Away
Last summer I mentioned a shareholder lawsuit against Schering-Plough over the way that the ENHANCE clinical data were handled for Vytorin. One of the interesting features here is that the plaintiffs are claiming that the company knew that the clinical trial was showing troublesome data, but elected to sit on the numbers for as long as possible - and they're introducing a series of posts on Cafe Pharma as evidence. These seem to foretell the 2008 announcement of the bad numbers in early 2007, with disturbing accuracy.
Now, as Jim Edwards points out, this case has not gone away. In fact, the most recent attempt to get it thrown out has failed, and former CEO Fred Hassan faces a possible deposition on the matter. This will be quite interesting to watch, since Merck is on the hook for any judgments that might result. Stay tuned. . .
+ TrackBacks (0) | Category: Business and Markets | Cardiovascular Disease | The Dark Side
POST A COMMENT
- RELATED ENTRIES
- How Not to Do It: NMR Magnets
- Allergan Escapes Valeant
- Vytorin Actually Works
- Fatalities at DuPont
- The New York TImes on Drug Discovery
- How Are Things at Princeton?
- Phage-Derived Catalysts
- Our Most Snorted-At Papers This Month. . .